Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen. However, new data due to be presented ...

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money.